Blue Lake Biotechnology, Inc., a clinical-stage company focused on intranasal vaccines using parainfluenza virus 5 (PIV5) vectors, and its affiliate CyanVac LLC, announced the presentation of positive interim pediatric clinical data for BLB201, their vaccine candidate targeting respiratory syncytial virus (RSV), at the 2024 ISV Annual Congress in Seoul, South Korea. The oral presentation also covered Phase 1 clinical data for CVXGA, their vaccine candidate against COVID-19.
Hong Jin, Ph.D., Chief Scientific Officer of Blue Lake Biotechnology and CyanVac, presented at the 2024 ISV Annual Congress on “PIV5-Vectored RSV and COVID-19 Intranasal Vaccines Show Great Promise in Clinical Studies.” His talk included interim analysis results from RSV-seropositive children in the ongoing Phase 1/2a pediatric study, demonstrating the safety and immunogenicity of BLB201. The data showed RSV F-specific systemic and mucosal antibody responses, as well as CD4+ and CD8+ T cell-mediated immune responses. Similar responses were observed for COVID S in the Phase 1 trial of CVXGA.
“Our vaccine approach aims to stimulate robust immune responses across humoral, cellular, and mucosal pathways,” said Biao He, Ph.D., CEO of Blue Lake and CyanVac. “Traditional vaccines, like mRNA and protein-based ones, often fail to induce mucosal immunity when administered intramuscularly. Our intranasal vaccine could prevent disease transmission and provide longer-lasting immunity.”
Additionally, Cristina Gingerich, Ph.D., a scientist at CyanVac, will present preclinical data on a PIV5-based vaccine for Lyme disease in a poster titled “An intranasal parainfluenza virus 5 (PIV5)-based vaccine for Lyme Disease induces protection against multi-strain Borrelia burgdorferi tick challenge in mice.” This project was a collaboration between CyanVac and Immuno Technologies, Inc., supported by the National Institute of Allergy and Infectious Diseases under award number R44AI167605.
About CyanVac and Blue Lake Biotechnology
CyanVac LLC and its affiliate, Blue Lake Biotechnology, Inc., are developing intranasal vaccines designed to harness the full immune response to prevent serious infectious diseases and protect vulnerable populations. Their proprietary parainfluenza virus 5 vector incorporates foreign genes from targeted pathogens, creating a robust clinical-stage pipeline of vaccines that aim to overcome existing technology limitations. Their lead candidates have shown potential for high efficacy and durability with minimal side effects.
